Collegium Pharmaceutical, Inc.
COLL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $631 | $567 | $464 | $277 |
| % Growth | 11.4% | 22.2% | 67.6% | – |
| Cost of Goods Sold | $254 | $241 | $254 | $126 |
| Gross Profit | $377 | $326 | $209 | $151 |
| % Margin | 59.8% | 57.5% | 45.2% | 54.4% |
| R&D Expenses | $0 | $0 | $4 | $9 |
| G&A Expenses | $172 | $0 | $0 | $0 |
| SG&A Expenses | $183 | $159 | $172 | $119 |
| Sales & Mktg Exp. | $11 | $0 | $0 | $0 |
| Other Operating Expenses | $24 | $0 | $0 | $5 |
| Operating Expenses | $207 | $159 | $176 | $133 |
| Operating Income | $170 | $167 | $33 | $18 |
| % Margin | 26.9% | 29.5% | 7.2% | 6.4% |
| Other Income/Exp. Net | -$71 | -$91 | -$62 | -$21 |
| Pre-Tax Income | $99 | $76 | -$29 | -$3 |
| Tax Expense | $29 | $28 | -$4 | -$75 |
| Net Income | $69 | $48 | -$25 | $72 |
| % Margin | 11% | 8.5% | -5.4% | 25.8% |
| EPS | 2.14 | 1.6 | -0.74 | 2.05 |
| % Growth | 33.8% | 316.2% | -136.1% | – |
| EPS Diluted | 1.86 | 1.29 | -0.74 | 1.86 |
| Weighted Avg Shares Out | 32 | 34 | 34 | 35 |
| Weighted Avg Shares Out Dil | 40 | 42 | 34 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $16 | $1 | $0 |
| Interest Expense | $74 | $83 | $63 | $21 |
| Depreciation & Amortization | $169 | $149 | $139 | $69 |
| EBITDA | $342 | $308 | $173 | $87 |
| % Margin | 54.1% | 54.4% | 37.4% | 31.3% |